Human cancers can be divided into two major categories, familial cancers and sporadic cancers (reviewed in [@bib7]). Familial cancers occur within affected families at a relatively high frequency and include a number of cancer syndromes that are caused by germline mutations of genes with strong effects that are directly involved in tumorigenesis. In contrast, the majority of human cancers are sporadic forms that result from exposure to environmental carcinogens (reviewed in [@bib11]). Recent epidemiologic studies ([@bib31]; [@bib44]; [@bib45]), as well as studies that use animal models of cancer (reviewed in [@bib7]), have shown that common allelic variants within the genome can act to modify relative risk of cancer development resulting from environmental carcinogen exposure.

Genes that modify susceptibility to tumor development (hereafter referred to as tumor susceptibility genes) are low-penetrance genes with modest effects on cancer susceptibility that are involved in DNA repair, immune response, carcinogen metabolism, cellular proliferation, differentiation, and death, as well as other cancer-related mechanisms. The combined effects of multiple tumor susceptibility genes determine the overall susceptibility of an individual to the development of a particular type of cancer, with each gene acting to either increase or decrease susceptibility. Although the identification of specific genes that underlie tumor susceptibility loci has been difficult, genes that underlie several modifier loci, including *Psl1.2* (*Gsta4*), *Mom1* (*Pla2g2a*), *Pctr1* (*Cdkn2a*), *Skts13* (*Aurka*), *Skts14* (*Tgfb1*), *Mtes1* (*Sipa1*), and others have recently been identified and variants that affect both function and expression have been reported (reviewed in [@bib7]). Importantly, polymorphisms in these genes have also been associated with cancer risk in humans, demonstrating the utility of using animal models to identify genes that modify susceptibility to cancer (reviewed in [@bib7]).

The multistage model of mouse skin carcinogenesis is an excellent model for the study of human epithelial carcinogenesis, and genetic differences in susceptibility to multistage skin carcinogenesis have been known for many years ([@bib8]; [@bib54]; [@bib37]; [@bib17]). Our laboratory, as well as others, has identified genetic loci that modify susceptibility to skin tumor promotion by 12-*O*-tetradecanoylphorbol-13-acetate (TPA), showing that susceptibility to skin tumor promotion is a multigenic trait ([@bib35]; [@bib4]; [@bib34]; [@bib3]; [@bib36]; [@bib5]; [@bib43]; [@bib6]; [@bib20]). We previously mapped TPA promotion susceptibility loci to chromosomes (chr) 1 (*Psl3*), 2 (*Psl2*), 9 (*Psl1*), and 19 (*Psl4*) in genetic crosses of C57BL/6 with DBA/2 mice ([@bib4]; [@bib3]; [@bib5], [@bib6]) and recently reported that *Psl1* consists of at least two subloci, *Psl1.1* and *Psl1.2* ([@bib2]). From these earlier studies, glutathione S-transferase alpha 4 (*Gsta4*) was identified as a skin tumor promotion susceptibility gene that maps within the *Psl1.2* locus ([@bib2]). Furthermore, polymorphisms in *GSTA4* were found to be associated with risk of developing nonmelanoma skin cancer in humans ([@bib2]). In the current study, analyses of combinations of nested and contiguous subcongenic mouse strains suggest that at least two additional modifier genes underlie the *Psl1.1* locus and that at least four modifier genes, including *Gsta4*, underlie the *Psl1.2* locus, indicating that *Psl1* is a compound quantitative trait locus (QTL). Additionally, inheritance of the DBA/2 allele of four of these loci (*Psl1.1a*, *Psl1.2a*, *Psl1.2b*, *Gsta4*) results in increased sensitivity whereas inheritance of the DBA/2 allele of two loci (*Psl1.1b*, *Psl1.2c*) results in decreased sensitivity to skin tumor promotion. Analysis of genes with expression or amino acid variants that map to regions of nonequivalency \[chromosome regions that are not identical by descent (IBD)\] within these loci has led to the identification of several attractive candidate skin tumor promotion susceptibility genes.

Materials and Methods {#s1}
=====================

Mice {#s2}
----

C57BL/6 and DBA/2 mice were obtained from the Jackson Laboratory (Bar Harbor, ME). C57BL/6.Psl1^dba^ congenic mouse strains ([Figure 1](#fig1){ref-type="fig"}, [Table 1](#t1){ref-type="table"}, and [Table 2](#t2){ref-type="table"}) were developed as previously described ([@bib2]) and maintained by brother/sister mating. All mice were maintained in a specific pathogen-free environment in the vivarium at the University of Texas M.D. Anderson Cancer Center, Science Park---Research Division in accordance with institutional guidelines. Mice were housed five per plastic cage in an air-conditioned room at 24° ± 2°, had free access to food and water, and were exposed to a 12-hr light and dark cycle.

![Distal chromosome 9 haplotype maps of C57BL/6.Psl1^dba^ subcongenic strains used to fine map the (A) *Psl1.1* and (B) *Psl1.2* loci. Subcongenic mouse strain designations are indicated at the top of each figure. Gray bars indicate chromosomal regions inherited from DBA/2. Black bars indicate chromosomal regions inherited from C57BL/6. Yellow bars indicate chromosomal regions with unknown genotype. Genetic markers used to genotype the congenic strains are listed on the left along with map locations in bases from the centromere. Lines to the right of the maps indicate the minimal region of interest for each *Psl1* sublocus. Gene symbols on the far right of the maps show the approximate map location of genes discussed in the paper. Those in red have expression variants, those in blue have amino acid variants, and those in green have both expression and amino acid variants.](1071f1){#fig1}

###### Tumor response of C57BL/6.Psl1.1 subcongenic strains

  Substrain[*^a^*](#t1n1){ref-type="table-fn"}   Introgressed Region   Length, Mb   6.8 nmol TPA   13.6 nmol TPA                                        
  ---------------------------------------------- --------------------- ------------ -------------- --------------- -------- ----------- ---- ---------- ----------
  A                                              D9Mit316 - telomere   59.0         2.4 ± 1.6      30              0.0179   8.6 ± 3.2   29   \<0.0001   \<0.0001
  E                                              Chst2 - telomere      29.2         1.8 ± 1.5      30              0.3314   4.4 ± 2.8   30   0.3686     \>0.1
  E6                                             D9Mit12 - D9Mit53     4.9          3.2 ± 2.1      30              0.0005   ND                          
  G                                              D9Mit346 - telomere   23.7         3.0 ± 2.1      30              0.0017   5.6 ± 2.7   30   0.0315     0.0005
  G5                                             D9Mit346 - D9Mit310   5.4          2.4 ± 1.5      29              0.0054   ND                          
  P                                              D9Mit115 - telomere   22.5         4.4 ± 3.9      30              0.0003   6.5 ± 4.4   30   0.0526     0.0002
  S                                              D9Mit80 - telomere    19.0         2.0 ± 1.6      29              0.2151   5.7 ± 3.4   30   0.1123     \>0.1
  C57BL/6                                                                           1.6 ± 1.2      30                       4.4 ± 2.3   29              

DMBA, 7,12-dimethylbenz\[a\]anthracene; TPA, 12-*O*-tetradecanoylphorbol-13-acetate; ND, not done.

Mice were initiated with 100 nmol DMBA and promoted twice weekly with 6.8 nmol TPA for 40 wks or 13.6 nmol TPA for 35 wks.

Tumors/mouse ± SD.

Number of mice at risk.

Significance level of tumor multiplicity compared to C57BL/6. Not adjusted for multiple testing.

*P* values combined using the Fischer's combined probability test (d.f. = 4). Not adjusted for multiple testing.

###### Tumor response of C57BL/6.Psl1.2 subcongenic strains

  Substrain[*^a^*](#t2n1){ref-type="table-fn"}   Introgressed Region   Length, Mb   Tumor Multiplicity[*^b^*](#t2n2){ref-type="table-fn"}   N[*^c^*](#t2n3){ref-type="table-fn"}   P[*^d^*](#t2n4){ref-type="table-fn"}
  ---------------------------------------------- --------------------- ------------ ------------------------------------------------------- -------------------------------------- --------------------------------------
  A                                              D9Mit316 - telomere   59.00        2.0 ± 1.9                                               30                                     0.005
  B                                              D9Mit316 - Chst2      30.60        0.8 ± 0.7                                               26                                     \>0.1
  B4                                             D9Mit316 - D9Mit239   28.40        1.5 ± 1.6                                               30                                     0.04
  B9                                             D9Mit316 - D9Mit196   20.80        1.5 ± 1.6                                               30                                     0.03
  BH1                                            D9Mit263 - D9Mit307   7.60         1.9 ± 1.6                                               30                                     0.0006
  H                                              D9Mit316 - Gsta4      13.10        1.5 ± 1.2                                               30                                     0.0072
  ^1^H                                           D9Mit316 - D9Mit302   2.00         1.3 ± 1.1                                               30                                     0.02
  H2                                             D9Mit316 - D9Mit260   3.70         2.3 ± 1.7                                               17                                     0.0012
  H3                                             D9Mit303 - D9Mit75    4.60         1.7 ± 2.0                                               30                                     0.02
  H4                                             D9Mit337 - D9Mit75    5.40         2.0 ± 1.3                                               30                                     0.0001
  H6                                             D9Mit166 - Gsta4      5.00         1.3 ± 1.4                                               30                                     0.09
  H7                                             D9Mit337 - Gsta4      10.60        2.1 ± 1.8                                               30                                     0.001
  C57BL/6                                                                           0.8 ± 1.1                                               30                                     

DMBA, 7,12-dimethylbenz\[a\]anthracene; TPA, 12-*O*-tetradecanoylphorbol-13-acetate.

Mice were initiated with 100 nmol of DMBA and promoted twice weekly with 6.8 nmol TPA for 36 wks.

Tumors/mouse ± SD.

Number of mice at risk.

Significance level of tumor multiplicity compared to C57BL/6. Not adjusted for multiple testing.

Reagents {#s3}
--------

TPA was purchased from LC Laboratories (Woburn, MA), and 7,12-dimethylbenz\[a\]anthracene (DMBA) was purchased from Sigma-Aldrich (St. Louis, MO).

Tumor experiments {#s4}
-----------------

Tumor experiments were carried out as previously described ([@bib1]) with female mice. A standard area on the dorsal skin extending from the base of the tail to the base of the head was shaved on each mouse. Forty-eight hours later, mice were initiated by topical treatment of 100 nmol of DMBA in 0.2 mL of acetone to the shaved area. Two weeks later, mice were treated with either 6.8 or 13.6 nmol of the tumor promoter TPA twice weekly until the tumor response reached a plateau. Mice were checked weekly for the appearance of papillomas. Tumor multiplicity was calculated as the cumulative number of papillomas observed divided by the number of mice at risk when the first tumor was observed.

Candidate genes {#s5}
---------------

The list of genes located under each QTL was downloaded from Ensembl, Build 37. A gene was considered as a candidate if the gene (1) was located within a region that differed in the haplotype of C57BL/6 and DBA/2; (2) had a nonsynonymous coding polymorphism between C57BL/6 and DBA/2; or (3) was differentially expressed in the epidermis of C57BL/6 and DBA/2.

Two-strain haplotype analysis {#s6}
-----------------------------

Single-nucleotide polymorphism (SNP) datasets of the C57BL/6 and DBA/2 inbred strains from the Imputed Diversity Array, Build 37 were used with the Mouse Strain Comparison Tool (The Center for Genome Dynamics at The Jackson Laboratory; <http://cgd.jax.org/straincomparison/>) to identify genetic intervals within the *Psl1* region considered equivalent (*i.e.*, IBD) between C57BL/6J and DBA/2J, where there were at least 10 consecutive SNP calls that matched. Other regions of *Psl1* were considered to be nonequivalent and genes within the nonequivalent regions were identified. Because of the high density of the SNPs and the nonuniformity of the SNP distribution within the genome, genes located within 10 Kb of the nonequivalent regions were also included.

Nonsynonymous coding polymorphisms {#s7}
----------------------------------

The dbSNP Build 128 available from the Mouse Genome Database (*[www.informatics.jax.org/](http://www.informatics.jax.org/)*) was used to identify any nonsynonymous coding polymorphism between C57BL/6J and DBA/2J. The potential functionality of these polymorphisms was evaluated using the Sorts Intolerant From Tolerant (SIFT) tool (<http://sift.jcvi.org/>) ([@bib38]). If the polymorphism was characterized as "damaging" or it led to a stop codon, the amino acid change was considered to be functional.

Gene expression analysis {#s8}
------------------------

For analysis of gene expression, the dorsal skin of female mice (7−9 wk of age) was shaved 48 hr before treatment. Mice (three mice per group) were treated twice weekly for 2 weeks topically with 0.2 mL of acetone (for controls) or TPA (6.8 nmol) in 0.2 mL of acetone. Mice were killed by cervical dislocation at various times after the final treatment and the treated skin was excised. Total RNA was extracted from the epidermis as previously described ([@bib48]). Expression ratios for individual genes were examined by microarray analyses (see [Supporting Information](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/009688SI.pdf), [Table S1](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS1.xlsx)). Expression of all genes found by microarray analyses to be differentially expressed 2-fold or greater was also analyzed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR; see [Table S2](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS2.pdf)) to verify differential expression. In addition, expression of several genes thought to be potential candidate genes, based on their roles in carcinogenesis but not found to be differentially expressed by microarray analysis, were measured by qRT-PCR. Microarray analyses were conducted using Illumina Mouse WG-6 v2 BeadArray (Illumina, Inc., San Diego, CA). Target preparation, hybridization, and scanning were conducted by the DNA Discovery Core of the University of Tennessee Health Science Center of Genomics and Bioinformatics (University of Tennessee, Memphis) using methods suggested by the manufacturer. qRT-PCR analysis of gene expression for *Hras1* was performed using primers and probe as previously described ([@bib48]). qRT-PCR analyses of all other genes used TaqMan gene expression assays (see [Table S3](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS3.pdf)) (Applied Biosystems, Foster City, CA). For relative quantification of expression, samples were normalized to the geometric means of the levels of Hras mRNA and 18S RNA, which were previously shown to be stable and useful as reference genes in this system ([@bib48]).

Statistical analysis {#s9}
--------------------

Statistical analyses of differences between tumor multiplicity for each mouse strain were evaluated using the Mann--Whitney *U*-test included in the Prism 5 software package (GraphPad Software, La Jolla, CA). A one-tailed test was used for analyses between tumor multiplicities of C57BL/6 and all other strains. A two-tailed test was used for analyses between tumor multiplicities between any two congenic strains. The Fisher's combined probability test was used to evaluate the combined results of independent experiments ([Table 1](#t1){ref-type="table"}). Comparisons of normalized mRNA levels were evaluated using a standard two-sided Student's *t*-test. A *P*-value of 0.05 or less was considered statistically significant.

Results {#s10}
=======

As noted in the *Introduction*, the skin tumor promotion susceptibility locus, *Psl1*, maps to the distal half of chr 9 ([@bib4], [@bib5], [@bib7]; [@bib3]; [@bib2]). We recently reported that when initiated with 2.5 μmol of *N*-methyl-*N*′-nitro-*N*-nitrosoguanidine (MNNG) and promoted twice weekly with 13.6 nmol of TPA for 36 weeks, the congenic mouse strain, C57BL/6.Psl1A^dba^, which inherited a 59.1-Mb region of chr 9 (distal to *D9Mit316*) from DBA/2 ([Figure 1](#fig1){ref-type="fig"}), was significantly more sensitive to skin tumor promotion than C57BL/6 controls ([@bib2]). Similar results were observed in the current studies when C57BL/6.Psl1A^dba^ mice were initiated with 100 nmol DMBA and promoted twice weekly with either 6.8 or 13.6 nmol of TPA ([Table 1](#t1){ref-type="table"} and [Table 2](#t2){ref-type="table"}), further supporting the previous conclusion that the genes underlying the *Psl1* locus have an effect on tumor promotion rather than tumor initiation. Furthermore, analysis of the tumor response of C57BL/6.Psl1B^dba^ and C57BL/6.Psl1E^dba^ subcongenic strains ([Figure 1](#fig1){ref-type="fig"}) initiated with 2.5 μmol of MNNG and promoted twice weekly with 13.6 nmol of TPA suggested that *Psl1* consisted of at least two subloci, *Psl1.1* and *Psl1.2*, that modify susceptibility to skin tumor promotion ([@bib2]). To further refine the map location of these subloci, additional interval specific C57BL/6.Psl1^dba^ subcongenic mouse strains were developed ([Figure 1](#fig1){ref-type="fig"}, [Table 1](#t1){ref-type="table"}, and [Table 2](#t2){ref-type="table"}) and tested for sensitivity to skin tumor promotion by TPA.

Fine mapping of the *Psl1.1* sublocus {#s11}
-------------------------------------

To fine map the *Psl1.1* sublocus, the response of interval specific subcongenic mouse strains ([Table 1](#t1){ref-type="table"} and [Figure 1A](#fig1){ref-type="fig"}) to skin tumor promotion with TPA was examined via a standard protocol. Mice were initiated with 100 nmol of DMBA and promoted twice weekly with 6.8 or 13.6 nmol of TPA until the tumor response reached a plateau ([Table 1](#t1){ref-type="table"}). C57BL/6.Psl1G^dba^, C57BL/6.Psl1P^dba^, and C57BL/6.Psl1E6^dba^ were significantly more sensitive than C57BL/6 mice to skin tumor promotion by TPA whereas the tumor response of C57BL/6.Psl1S^dba^ was similar to that of C57BL/6 ([Table 1](#t1){ref-type="table"}). These data are consistent with other studies in which mice were initiated with MNNG (J. M. Angel and J. DiGiovanni, unpublished data). These results suggest that one or more genes mapping to a 3.2-Mb region of chr 9 between *D9Mit115* and *D9Mit53* modifies susceptibility to skin tumor promotion by TPA. This locus has been designated *Psl1.1a* ([Figure 1A](#fig1){ref-type="fig"}). The observation that C57BL/6.Psl1G5^dba^ mice were significantly more sensitive than C57BL/6 mice ([Table 1](#t1){ref-type="table"}) to skin tumor promotion by TPA is consistent with the mapping of a locus to this region. Inheritance of *Psl1.1a* from DBA/2 results in increased sensitivity to skin tumor promotion.

C57BL/6.Psl1E^dba^ mice, which are homozygous for the DBA/2 allele of *Psl1.1a* ([Figure 1A](#fig1){ref-type="fig"}), had a tumor response similar to that of C57BL/6 when initiated with 100 nmol of DMBA and promoted twice weekly with either 6.8 or 13.6 nmol TPA ([Table 1](#t1){ref-type="table"}). The observations that C57BL/6.Psl1E6 mice are sensitive whereas C57BL/6.Psl1E mice are resistant to skin tumor promotion ([Table 1](#t1){ref-type="table"}) suggest that one or more genes mapping to a 5.5-Mb region of chr 9 between *D9Mit112* and *D9Mit346* modify susceptibility to skin tumor promotion by TPA. This locus has been designated *Psl1.1b* ([Figure 1A](#fig1){ref-type="fig"}), and inheritance of this locus from DBA/2 results in decreased sensitivity to skin tumor promotion by TPA.

Fine mapping of the *Psl1.2* sublocus {#s12}
-------------------------------------

To fine map the *Psl1.2* sublocus, additional interval specific subcongenic strains ([Table 2](#t2){ref-type="table"}, [Figure 1B](#fig1){ref-type="fig"}) were analyzed for their susceptibility to skin tumor promotion with TPA. Again, mice were initiated with 100 nmol of DMBA and promoted twice weekly with 6.8 nmol of TPA until the tumor response reached a plateau ([Table 2](#t2){ref-type="table"}). The observations that C57BL/6.Psl1BH1^dba^ mice were more sensitive than C57BL/6 mice ([Table 2](#t2){ref-type="table"}) and that C57BL/6.Psl1H6^dba^ mice had a tumor response similar to C57BL/6 ([Table 2](#t2){ref-type="table"}) are consistent with the conclusion that *Gsta4* is a tumor promotion susceptibility gene as recently reported ([@bib2]).

C57BL/6.Psl1H^dba^ mice were also significantly more sensitive than C57BL/6 mice to skin tumor promotion by TPA. These data are consistent with other studies in which mice were initiated with MNNG (J. M. Angel and J. DiGiovanni, unpublished data) suggesting that one or more genes mapping proximal to *Gsta4* modify susceptibility to skin tumor promotion. Additional subcongenic strains were analyzed for skin tumor promotion susceptibility to further delimit this region. Both C57BL/6.Psl1H1^dba^ and C57BL/6.Psl1H3^dba^ had similar tumor responses that were significantly greater than that of C57BL/6 ([Table 2](#t2){ref-type="table"}). Furthermore, C57BL/6.Psl1H2^dba^ mice were significantly more sensitive to skin tumor promotion by TPA than either C57BL/6.Psl1H1^dba^ (*P* = 0.02) or C57BL/6.Psl1H3^dba^ (*P* = 0.05) mice and had a tumor response similar to the combined response of C57BL/6.Psl1H1^dba^ and C57BL/6.Psl1H3^dba^ (data not shown). Taken together, these data suggest that at least two genes that modify susceptibility to skin tumor promotion by TPA map between *D9Mit316* and *D9Mit260*. One locus, *Psl1.2a* ([Figure 1B](#fig1){ref-type="fig"}), maps to a region of chr 9 between *D9Mit316* and *D9Mit302* whereas the second locus, *Psl1.2b* ([Figure 1B](#fig1){ref-type="fig"}), maps to a region of chr 9 between *D9Mit303* and *D9Mit260*. The observations that C57BL/6.Psl1H4^dba^ and C57BL/6.Psl1H7^dba^ mice were also significantly more sensitive than C57BL/6 mice to skin tumor promotion ([Table 2](#t2){ref-type="table"}) suggest that the map location of *Psl1.2b* can be narrowed to a region of chr 9 between *D9Mit337* and *D9Mit260* ([Figure 1B](#fig1){ref-type="fig"}). However, the possibility that the sensitivity of these two strains is due to a third skin tumor promotion susceptibility locus mapping between *D9Mit260* and *D9Mit75* cannot be ruled out at the present time. Inheritance of either *Psl1.2a* or *Psl1.2b* from DBA/2 results in increased susceptibility to skin tumor promotion by TPA.

The tumor response of C57BL/6.Psl1B^dba^ mice was similar to that of C57BL/6 mice when initiated with 100 nmol of DMBA and promoted twice weekly with 6.8 nmol of TPA ([Table 2](#t2){ref-type="table"}). The observation that C57BL/6.Psl1B^dba^ mice were relatively resistant to skin tumor promotion by TPA, even though they inherited the susceptibility alleles of *Psl1.2a*, *Psl1.2b*, and *Gsta4* from DBA/2, suggests that a fourth gene mapping distal to *D9Mit306* causes a decrease in skin tumor promotion susceptibility when inherited from DBA/2. To further narrow the map location of this gene, the tumor response of two additional subcongenic mouse strains, C57BL/6.Psl1B4^dba^ and C57BL/6.Psl1B9^dba^ ([Table 2](#t2){ref-type="table"}, [Figure 1B](#fig1){ref-type="fig"}), was examined. Both strains were significantly more sensitive than C57BL/6 mice to skin tumor promotion by TPA ([Table 2](#t2){ref-type="table"}), suggesting that a resistance locus maps to a region of chr 9 between *D9Mit238* and *Chst2*. This locus has been designated *Psl1.2c* ([Figure 1B](#fig1){ref-type="fig"}).

Characterization of the *Psl1.1a* locus {#s13}
---------------------------------------

Potential candidate genes can be identified with haplotype mapping, which takes advantage of the fact that laboratory strains of mice were derived from the same founders and share regions of the genome that are IBD ([@bib61]). Haplotype blocks in which the two parental strains are not IBD are the most probable location for causal genetic variation ([@bib58]). Two-strain haplotype analysis, comparing C57BL/6 and DBA/2 haplotypes as described in the *Materials and Methods* section, were conducted to identify regions of the *Psl1* locus that are not IBD (nonequivalent), and genes mapping to these regions were identified. Of 24 protein-coding genes that map to *Psl1.1a*, 15 map to regions of nonequivalency. In addition, one microRNA gene (*Mir2136*) and one long intergenic noncoding RNA (*Gm17708*) map to the *Psl1.1a* locus, both in regions of nonequivalency.

Different alleles of a candidate gene that underlie a QTL must display either an expression or functional variant. Twenty-two of the 24 protein-coding genes mapping to the *Psl1.1a* locus were analyzed by microarray and/or qRT-PCR for mRNA levels in the epidermis of TPA-treated C57BL/6 and DBA/2 mice 6 hr after the last of twice-weekly treatments for 2 wk. Nine of these protein-coding genes that map to regions of nonequivalency were found to be expressed above background (see [Table S1](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS1.xlsx) and [Table S2](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS2.pdf)), and three of these genes, chemokine (c-c motif) receptor-like 1 (*Ccrl1*), prostate acid phosphatase (*Accp*), and receptor-like tyrosine kinase (*Ryk*), were differentially expressed in the epidermis of C57BL/6 compared with DBA/2 mice 6 hr after the final TPA treatment ([Figure 1A](#fig1){ref-type="fig"} and [Table 3](#t3){ref-type="table"}). Four other genes examined by qRT-PCR were found to be differentially expressed at other time points, with mRNA levels being greater in the epidermis of C57BL/6 compared with DBA/2 mice for angiomotin-like 2 (*Amotl2*) and kyphoscoliosis peptidase (*Ky*) and greater in TPA-treated DBA/2 compared with C57BL/6 epidermis for transmembrane protein 108 (*Tmem108*) and Eph receptor B1 (*Ephb1*) (data not shown). These genes may also be candidate promotion susceptibility genes. Interestingly, *Rab6b*, which maps within a region of IBD, was also differentially expressed in the epidermis of TPA-treated C57BL/6 compared with DBA/2 mice (data not shown), suggesting that expression of this gene may be regulated in *trans*.

###### Potential candidate genes differentially expressed in the epidermis of TPA-treated C57BL/6 *vs.* DBA/2 mice

  Locus          Map Location   Gene Symbol   C57BL/DBA[*^a^*](#t3n1){ref-type="table-fn"}   
  -------------- -------------- ------------- ---------------------------------------------- -----
  Psl1.1a        102737250      Ryk           1.0                                            2.4
  Psl1.1a        104000468      Ccrl1         1.4                                            5.5
  Psl1.1a        104190570      Acpp          3.5                                            5.2
  Psl1.1b        99210386       Esyt3         2.8                                            4.6
  Psl1.2a or b   66870400       Tpm1          2.0                                            6.4

qRT-PCR, quantitative reverse transcription polymerase chain reaction.

Mice were treated twice weekly for 2 wk with 6.8 nmol of TPA in 0.2 mL of acetone and killed 6 hr after the final treatment.

Comparison of DNA sequences between C57BL/6 and DBA/2 identified nonsynonymous SNPs for three protein-coding genes and one unclassified noncoding RNA gene, *Gm5627*, mapping to the *Psl1.1a* locus. Two of these genes, nephronophthisis 3 (adolescent) (*Nphp3*, [Figure 1A](#fig1){ref-type="fig"}) and acyl-Coenzyme A dehydrogenase family, member 11 (*Acad11*, [Figure 1A](#fig1){ref-type="fig"}), which were found to be expressed in the epidermis by qRT-PCR (see [Table S2](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS2.pdf)), were considered to be potential candidate genes. The *Nphp3* SNP was predicted to be tolerated in the SIFT database ([Table 4](#t4){ref-type="table"}).

###### Potential candidate genes with nonsynonymous SNPs that map to Psl1 subloci

  Locus     Map Location   Gene Symbol   SIFT
  --------- -------------- ------------- ----------
  Psl1.1a   103904874      Nphp3         T
  Psl1.1a   103966033      Acad11        NF
  Psl1.1b   96585842       Zbtb38        T
  Psl1.1b   99210386       Esyt3         NF
  Psl1.1b   99356662       Nme9          T
  Psl1.1b   99378810       Armc8         Damaging
  Psl1.1b   99530014       Dzip1l        NF
  Psl1.2a   65142102       Clpx          NF
  Psl1.2a   65283589       Mtfmt         T
  Psl1.2a   65515808       Oaz2          NF
  Psl1.2a   65676733       Trip4         T
  Psl1.2a   65935934       Snx1          NF
  Psl1.2a   66198257       Herc1         T
  Psl1.2a   66561493       Car12         T

SNP, single-nucleotide polymorphism; SIFT, Sorts Intolerant From Tolerant; T, tolerated; NF, not found in database.

Characterization of the *Psl1.1b* locus {#s14}
---------------------------------------

Of 49 protein-coding genes that map to *Psl1.1b*, 35 map to regions of nonequivalency. Thirty-nine of the 49 protein-coding genes mapping to the *Psl1.1b* locus were analyzed by microarray and/or qRT-PCR for mRNA levels in the epidermis of TPA-treated C57BL/6 and DBA/2 mice 6 hr after the last of twice weekly treatments for 2 wk. Twenty-one genes that map to regions of nonequivalency were found to be expressed above background (see [Table S1](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS1.xlsx) and [Table S2](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS2.pdf)). mRNA levels of one protein-coding gene, extended synaptotagmin-like protein 3 (*Esyt3*, [Figure 1A](#fig1){ref-type="fig"}), were found to be \>2-fold greater in the epidermis of C57BL/6 than DBA/2 mice ([Table 3](#t3){ref-type="table"}). Therefore, *Esyt3* was considered to be a potential candidate gene.

Comparison of C57BL/6 and DBA/2 sequences identified six protein-coding genes with nonsynonymous SNPs mapping to the *Psl1.1b* locus. One of these genes was not expressed above background when examined by microarray. The remaining five genes ([Table 4](#t4){ref-type="table"} and [Figure 1A](#fig1){ref-type="fig"}) were considered to be potential candidate genes. SNPs for three genes were found in the SIFT database ([Table 4](#t4){ref-type="table"}) and the nonsynonoymous SNP for one of these genes, armadillo repeat containing 8 (*Armc8*, [Table 4](#t4){ref-type="table"}), was predicted to be damaging.

Characterization of the *Psl1.2a* locus {#s15}
---------------------------------------

Of 36 protein-coding genes that map to *Psl1.2a*, 25 map to regions of nonequivalency. Four unclassified noncoding RNA genes map to the *Psl1.2a* locus, all in regions of nonequivalency. Thirty-three of the 36 protein-coding genes mapping to the *Psl1.2a* locus were analyzed by microarray and/or qRT-PCR for mRNA levels in the epidermis of TPA-treated C57BL/6 and DBA/2 mice 6 hr after the last of twice weekly treatments for 2 wk. Of those genes that mapped to regions of nonequivalency, 18 were expressed above background (see [Table S1](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS1.xlsx) and [Table S2](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS2.pdf)). mRNA levels of one protein-coding gene, tropomyosin 1, alpha (*Tpm1*, [Figure 1B](#fig1){ref-type="fig"}), were found to be \>2-fold greater in the epidermis of C57BL/6 than DBA/2 mice ([Table 3](#t3){ref-type="table"}). Therefore, *Tpm1* was considered to be a potential candidate gene.

Comparison of the DNA sequences of C57BL/6 and DBA/2 identified eight protein-coding genes with nonsynonymous SNPs that map to the *Psl1.2a* locus. One of these genes was determined by microarray analysis to not be expressed above background. The remaining genes ([Table 4](#t4){ref-type="table"} and [Figure 1B](#fig1){ref-type="fig"}) were considered to be candidate genes. Nonsynonymous SNPs found in four of these genes were found in the SIFT database and all four were predicted to be tolerated ([Table 4](#t4){ref-type="table"}).

Characterization of the *Psl1.2b* locus {#s16}
---------------------------------------

Of 12 protein-coding genes that map to *Psl1.2b*, seven map to regions of nonequivalency. One microRNA and two noncoding RNA genes map to the *Psl1.2b* locus and are found in regions of nonequivalency. Nine of the 12 protein-coding genes mapping to the *Psl1.2b* locus were analyzed by microarray for mRNA levels in the epidermis of TPA-treated C57BL/6 and DBA/2 mice 6 hr after the last of twice weekly treatments for 2 wk. Of those genes, four mapped to regions of nonequivalency and were expressed above background (see [Table S1](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS1.xlsx) and [Table S2](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS2.pdf)). mRNA levels of *Tpm1* were found to be ≥2-fold greater in the epidermis of C57BL/6 than DBA/2 mice ([Table 3](#t3){ref-type="table"}). *Tpm1* maps to a region of overlap for the *Psl1.2a* and *Psl1.2b* loci ([Figure 1B](#fig1){ref-type="fig"}) and was considered a potential candidate gene for either locus.

Comparison of the DNA sequences of C57BL/6 and DBA/2 identified two protein-coding genes with nonsynonymous SNPs that map to the *Psl1.2b* locus. Microarray analysis indicated that neither of these genes was expressed above background in the epidermis of acetone- or TPA-treated C57BL/6 or DBA/2 mice 6 hr after the last of four treatments.

Characterization of the *Psl1.2c* locus {#s17}
---------------------------------------

Three protein-coding genes map to the *Psl1.2c* locus, and two of these genes map to a region of nonequivalency. Neither of these genes was differentially expressed in the epidermis after the last of four treatments with TPA (see [Table S1](http://www.g3journal.org/lookup/suppl/doi:10.1534/g3.113.009688/-/DC1/TableS1.xlsx)), and no nonsynonymous SNPs have been reported for either gene.

Discussion {#s18}
==========

The skin tumor promotion susceptibility locus, *Psl1*, was previously mapped to a 59.1-Mb region of mouse chr 9 ([@bib4], [@bib5], [@bib7]; [@bib3]) and the glutathione S-transferase gene, *Gsta4*, was shown to underlie at least some of the effect of this locus on skin tumor promotion susceptibility in mice ([@bib2]). In addition, *GSTA4* has been shown to be a modifier of susceptibility to nonmelanoma skin cancer in humans ([@bib2]). As described in the current study, analyses of skin tumor promotion susceptibility using interval specific subcongenic mouse strains indicate that *Psl1* is a compound locus made up of a cluster of subloci (see [Figure 1](#fig1){ref-type="fig"}), similar to other QTL affecting complex traits such as blood pressure (reviewed in [@bib47]), diabetes ([@bib22]), body composition ([@bib16]; [@bib18]; [@bib24]; [@bib46]), and cancer ([@bib49], [@bib50]). Inheritance of *Psl1.1a*, *Psl1.2a*, *Psl1.2b*, and *Gsta4* from DBA/2 results in increased susceptibility to skin tumor promotion whereas inheritance of *Psl1.1b* and *Psl1.2c* from DBA/2 results in decreased susceptibility. Although the skin tumor susceptibility locus, *Skts6*, was mapped to the distal half of chr 9 using crosses of Mus spretus with NIH/Ola mice ([@bib36]), it is not possible to determine from the current studies whether any of the *Psl1* subloci and *Skts6* are the same.

Of the more than 550 protein-coding genes that map within the *Psl1* locus, fewer than 25 genes that fulfill the criteria for candidate skin tumor promotion susceptibility genes were identified in the current study (summarized in [Table 3](#t3){ref-type="table"} and [Table 4](#t4){ref-type="table"}). For example, the receptor-like tyrosine kinase, *Ryk*, maps to the *Psl1.1a* locus and is expressed 2.6-fold greater in the epidermis of TPA-treated C57BL/6 compared with DBA/2 mice ([Table 3](#t3){ref-type="table"}). The receptor encoded by *Ryk* functions as a co-receptor with Frizzled for Wnt ligands and binds to Dishevelled, through which it activates the canonical Wnt Pathway ([@bib32]). A genetic variant of *RYK* has been associated with risk of breast cancer in humans ([@bib60]), supporting the hypothesis that *Ryk* may be a candidate tumor promotion susceptibility gene.

*Ccrl1* (*CCX-CKR*) also maps to the *Psl1.1a* locus and is expressed at greater levels in TPA-treated epidermis of C57BL/6 compared with DBA/2 mice ([Table 3](#t3){ref-type="table"}). CCRL1 is an atypical chemokine receptor that lacks a signaling domain. Overexpression of *CCRL1* inhibited proliferation and migration of human breast cancer cells both *in vitro* and *in vivo* ([@bib19]), supporting the hypothesis that *Ccrl1* is a cancer susceptibility gene. The CCRL1 protein selectively binds the homeostatic CC-chemokines CCL19, CCL21, and CCL25 ([@bib21]; [@bib56]; [@bib14]). Binding to CCRL1 results in internalization and degradation of these ligands ([@bib13]), which attenuates the immune response ([@bib23]). Recent reports have shown that the CCRL1 ligands promote proliferation and prevent apoptosis ([@bib59]; [@bib30]; [@bib53]; [@bib25]; [@bib63], [@bib64]), suggesting that increased expression of *Ccrl1* may reduce tumor response through chemokine depletion. This idea is further supported by the observation of a significantly higher rate of tumor growth in wild-type BALB/c mice compared to plt mice, which lack CCL19 and CCL21, implanted with a syngeneic squamous cell carcinoma cell line ([@bib33]).

Another potential candidate tumor promotion susceptibility gene, *Zbtb38* (zinc finger and BTB domain containing 38), maps to a region of nonequivalency within the *Psl1.1b* locus and has an amino acid variant between C57BL/6 and DBA/2 ([Table 4](#t4){ref-type="table"}). The protein encoded by *Zbtb38* is a member of the Kaiso-like family of methyl-CpG-binding proteins. It is a BTB-zinc finger transcriptional repressor that interacts with the transcriptional co-repressor C-terminal binding proteins ([@bib51]). C-terminal binding protein is thought to be involved in development and carcinogenesis (reviewed in [@bib9], [@bib10]). The protein encoded by *Zbtb38* has been identified as a substrate of caspase-3, and down-regulation induces apoptosis in mouse C2C12 cells ([@bib42]). Overexpression of *Zbtb38* in mouse embryonic stem cells promotes proliferation and accelerates G1/S transition whereas small interfering RNA knockdown of expression inhibits proliferation ([@bib40]). Taken together, these observations suggest that *Zbtb38* may play a role in carcinogenesis. Recently, a SNP in intron 4 of *ZBTB38* was associated with prostate cancer risk in a multistage genome-wide association study ([@bib28]), further supporting this hypothesis.

Armadillo repeat containing 8 (*Armc8*), which also maps to a region of nonequivalency within the *Psl1.1b* locus, has an amino acid variant between C57BL/6 and DBA/2 that may be damaging to protein function ([Table 4](#t4){ref-type="table"}). *Armc8* encodes two splice variants that contain armadillo-repeat motifs. Armadillo-repeat containing proteins are involved in diverse cellular functions such as intracellular signaling and cell-cell contact regulation ([@bib12]). Although Armc8 has not been shown to be directly involved in tumor development, it has been shown to regulate proteasome-dependent degradation of the tumor suppressor, α-catenin ([@bib55]). α-Catenin has recently been reported to regulate keratinocyte stem cell proliferation ([@bib52]). Loss of α-catenin triggers severe epidermal hyperplasia ([@bib57]) and xenografts of keratinocytes lacking α-catenin produced skin lesions in nude mice that resembled squamous cell carcinomas ([@bib27]). These observations suggest that *Armc8* may modify skin tumor promotion susceptibility through altered regulation of α-catenin degradation.

Sorting nexin 1 (*Snx1*) is a potential candidate promotion susceptibility gene for the *Psl1.2a* locus ([Table 4](#t4){ref-type="table"}). *SNX1* is a putative tumor suppressor gene ([@bib39]), and the encoded protein is a member of a large family of endocytic proteins that help determine the fate of internalized receptors as the receptors reach the early endosome ([@bib62]). It plays a role in targeting ligand-activated epidermal growth factor receptor (EGFR) to the lysosomes for degradation after endocytosis from the cell surface and release from the Golgi ([@bib29]). Small interfering RNA knockdown of *SNX1* levels in tumor cell lines resulted in increased proliferation, decreased apoptosis, decreased anoikis, increased EGFR phosphorylation after EGF stimulation, and increased downstream signaling ([@bib39]; [@bib41]). These results suggest that *Snx1*/*SNX1* may be involved in carcinogenesis by regulating ligand-induced EGFR phosphorylation and suggest a critical function for *Snx1*/SNX1 in the maintenance of tightly regulated EGFR-mediated signaling. The C57BL/6 allele of *Snx1* encodes a protein with a serine at amino acid 117, whereas the DBA/2 allele encodes a protein with a proline at this position. This nonconserved amino acid variant maps within the phospholipid-binding-motif termed the phox homology (PX) domain, which is involved in localizing the SNX1 protein to early endosomes ([@bib62]). A human variant of SNX1 with a point mutation (K214A) in the PX domain was incabable of binding 3-phosphoinositides and localized to the cytosol rather than to early endosomes ([@bib15]). Furthermore, the K214A variant could not stimulate EGFR degradation whereas the wild-type SNX1 did, indicating that the PX domain-dependent/early endosomal association of SNX1 is important for its ability to regulate the targeting of internalized EGFR for lysosomal degradation ([@bib15]). Additional studies will be required to determine whether the amino acid variant at position 117 in the mouse SNX1 protein has a similar effect and if this variant plays a role in skin tumor promotion susceptibility.

A recent study found that loss of expression of bone morphogenetic protein 5 (*Bmp5*), which maps to distal chr 9, was associated with reduction in size and number of clonogenic keratinocyte stem cells and an increase in sensitivity to skin tumor promotion ([@bib26]) suggesting that *Bmp5* may underlie a portion of the effect of *Psl1* on skin tumor promotion susceptibility. However, *Bmp5* does not map to any of the *Psl1* subloci identified in the present study ([Figure 1B](#fig1){ref-type="fig"}). Furthermore, the congenic mouse strain C57BL/6.Psl1H6^dba^, which has a tumor response similar to C57BL/6 when initiated with 100 nmol of DMBA and promoted twice weekly with 6.8 nmol of TPA ([Table 2](#t2){ref-type="table"}), inherited the DBA/2 allele of *Bmp5* ([Figure 1B](#fig1){ref-type="fig"}), indicating that *Bmp5* does not affect skin tumor promotion susceptibility in genetic crosses of C57BL/6 with DBA/2 mice.

In conclusion, at least six genes mapping to the *Psl1* locus on distal chr 9 modify susceptibility to skin tumor promotion by TPA. Previous studies have shown that one gene that resides in this region (*Gsta4*) is a modifier of skin tumor promotion susceptibility ([@bib2]). Other genes mapping to regions of nonequivalency within the *Psl1* subloci are either differentially expressed in the epidermis of resistant C57BL/6 *vs.* sensitive DBA/2 mice treated with TPA or have amino acid variants between the two strains of mice. Several of these genes have been associated with cancer risk in humans or play a role in signaling pathways associated with carcinogenesis, making them excellent candidate skin tumor promotion susceptibility genes. Additional studies will be required to confirm that these genes are modifiers of skin tumor promotion susceptibility.
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